Press Release Dec 30 2022
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This partnership aims to develop mRNA-based therapies, particularly for respiratory diseases, and enhance access to innovative treatments in emerging markets. The transaction is expected to complete within a specified timeframe, pending regulatory approvals. Umang Vohra, Cipla's CEO, emphasized the significance of this collaboration in advancing their innovation journey in healthcare solutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cipla
- Press Release Nov 29 2022
- Press Release Nov 04 2022
- Press Release Oct 11 2022
- Press Release Sep 07 2022
- Press Release Jul 29 2022
Later from Cipla
- Cipla Ltd Press Release Jan 18 2023
- Press Release Jan 25 2023
- Press Release May 12 2023
- Cipla Ltd Press Release Jul 07 2023
- Press Release Jul 26 2023
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla